Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 8/20 | 0.43 |
| ▸ | LCK | P06239 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.42 |
| ▸ | CASR | P41180 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15701130 | 0.87 | CYP2C9 (0.45) | MAPK14CYP2C9CYP2C8 | |
| SCHEMBL15701247 | 0.85 | LRRK2 (0.45) | EPHX2TRPV4CYP2C9CYP2C8CASR | |
| SCHEMBL15701225 | 0.84 | CASR (0.44) | EPHX2TRPV4CYP2C9CYP2C8CASR | |
| SCHEMBL19446803 | 0.83 | CYP2C9 (0.52) | MAPK14CYP2C9CYP2C8 | |
| SCHEMBL15701246 | 0.81 | LRRK2 (0.46) | TRPV4CYP2C9CYP2C8CASRTHRB | |
| SCHEMBL15701282 | 0.81 | CYP2C9 (0.40) | MAPK14CYP2C9CYP2C8 | |
| SCHEMBL19457525 | 0.79 | CYP2C9 (0.38) | CYP2C9CYP2C8 | |
| SCHEMBL15701081 | 0.78 | CYP2C9 (0.52) | MAPK14CYP2C9CYP2C8 | |
| SCHEMBL15701221 | 0.78 | CYP2C9 (0.49) | CYP2C9CYP2C8 | |
| SCHEMBL15701045 | 0.78 | CYP2C9 (0.52) | MAPK14CYP2C9CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2914592-B1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INT (DE) | 2017-10-11 | — | — | EP | disclosed |
| US-9334249-B2 | Inhibitors of cytomegalovirus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-10 | — | — | US | disclosed |
| US-9334249-B2 | Inhibitors of cytomegalovirus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-10 | — | — | US | disclosed |
| US-20150284348-A1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-08 | — | — | US | disclosed |
| US-20150284348-A1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-08 | — | — | US | disclosed |
| WO-2014070979-A1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284348-A1 | INHIBITORS OF CYTOMEGALOVIRUS | CDKN1A, CCNA1, IFNAR1 | EPHX2 3831/4885TRPV4 4858/4885LCK 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.